BE with 1 not included in CI -danish twist [RSABE / ABEL]

posted by d_labes  – Berlin, Germany, 2013-01-16 16:07 (4501 d 16:24 ago) – Posting: # 9866
Views: 5,668

My dear!

❝ 1.0 not included in the 90% CI should not keep you awake at night.


Did you really forgot the Danish twist? Although the power calculation for their "BE decision rule" was implemented in the famous EFG? Can't believe that :-D.

@Coja:
Your BE acceptance range is really wide. Where did it came from?

If your study is aimed for the European market no go! The widest acceptance range allowed in the EMA guidance is 69.84% ... 143.19% given that your study is a replicate crossover study and your intra-subject CV of the Reference from that study is >=50%. Note that the widening is only allowed for Cmax.

If your study is targeted to the FDA a simple widening of the acceptance range is not the correct method. Search the Forum for "scaled average bioequivalence" or "RSABE".

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
113 visitors (0 registered, 113 guests [including 77 identified bots]).
Forum time: 09:32 CEST (Europe/Vienna)

Don’t undertake a project
unless it’s manifestly important
and nearly impossible.    Edwin H. Land

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5